Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 4/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.40 |
| ▸ | GRM5 | P41594 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30939142 | 0.87 | HCRTR2 (0.37) | HCRTR2HCRTR1CYP11B1CYP11B2GRM5 | |
| SCHEMBL13571061 | 0.84 | EPHX2 (0.44) | HCRTR2HCRTR1CYP11B1CYP11B2GRM5 | |
| SCHEMBL13571312 | 0.83 | NUDT1 (0.46) | HCRTR2HCRTR1CYP11B1CYP11B2GRM5 | |
| SCHEMBL6247691 | 0.78 | GRM5 (0.36) | HCRTR2HCRTR1CYP11B1CYP11B2GRM5 | |
| SCHEMBL4930416 | 0.77 | GABRG2 (0.49) | HCRTR2HCRTR1CYP11B1CYP11B2GRM5 | |
| SCHEMBL22637463 | 0.77 | MGLL (0.39) | HCRTR2HCRTR1CYP11B1CYP11B2GRM5 | |
| SCHEMBL7471262 | 0.76 | HCRTR2 (0.33) | HCRTR2HCRTR1CYP11B1CYP11B2GRM5 | |
| SCHEMBL4182663 | 0.75 | MAPT (0.46) | HCRTR2HCRTR1EPHX2L3MBTL1SMN1; SMN2 | |
| SCHEMBL2694186 | 0.75 | L3MBTL1 (0.51) | HCRTR2HCRTR1CYP11B1CYP11B2EPHX2 | |
| SCHEMBL19999901 | 0.75 | GRM5 (0.38) | HCRTR2HCRTR1CYP11B1CYP11B2GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735423-A1 | KV7 MODULATORS | Saniona A/S (DK) | 2026-05-06 | — | — | EP | disclosed |
| US-20250282725-A1 | KCNQ POTENTIATORS | Eii Lilly and Company | 2025-09-11 | — | — | US | disclosed |
| US-12344584-B2 | KCNQ potentiators | ELI LILLY AND COMPANY (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2025003343-A1 | KV7 MODULATORS | SANIONA A/S (DK) | 2025-01-02 | — | — | WO | disclosed |
| US-20240076269-A1 | KCNQ POTENTIATORS | Eii Lilly and Company (US) | 2024-03-07 | — | — | US | disclosed |
| US-11840516-B2 | KCNQ potentiators | ELI LILLY AND COMPANY (US) | 2023-12-12 | — | — | US | disclosed |
| EP-3921030-B1 | 1-((2-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-4-YL)METHYL)UREA DERIVATIVES AS KCNQ POTENTIATORS | LILLY CO ELI (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20230271950-A1 | ANTIBACTERIAL PICOLINAMIDE COMPOUNDS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230271950-A1 | ANTIBACTERIAL PICOLINAMIDE COMPOUNDS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2023-08-31 | — | — | US | disclosed |
| WO-2023019912-A9 | BENZOTRIAZINE DIOXIDE AND PHARMACEUTICAL COMPOSITION THEREOF | 杭州瑞臻医药有限公司 | 2023-06-01 | — | — | WO | disclosed |
| US-20050153960-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2005-07-14 | — | — | US | disclosed |
| EP-1537084-A1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | Amgen Inc. (US) | 2005-06-08 | — | — | EP | disclosed |
| US-6878714-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2005-04-12 | — | — | US | disclosed |
| US-20040204437-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2004-10-14 | — | — | US | disclosed |
| WO-2004007457-A2 | SUBSTITUTED BENZYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004007458-A1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004007481-A2 | SUBSTITUTED AMINE DERIVATIVES AND METHODS OF USE IN THE TREATMENT OF ANGIOGENESIS RELATES DISORDERS | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-12-04 | — | — | US | disclosed |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-30 | — | — | US | disclosed |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282725-A1 | KCNQ POTENTIATORS | KCNN3, KCNQ1, KCNN1 | HCRTR2 4121/4885HCRTR1 3473/4885CYP11B1 2069/4885 |
| US-20050153960-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | HCRTR2 3524/4885HCRTR1 3439/4885CYP11B1 69/4885 |
| US-12344584-B2 | KCNQ potentiators | KCNN3, KCNQ1, KCNN1 | HCRTR2 4121/4885HCRTR1 3473/4885CYP11B1 2069/4885 |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | NAT1, PIGO, AADAC | HCRTR2 2904/4885HCRTR1 2745/4885CYP11B1 59/4885 |
| US-20040204437-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | HCRTR2 3524/4885HCRTR1 3439/4885CYP11B1 69/4885 |
| US-11840516-B2 | KCNQ potentiators | KCNN3, KCNQ1, KCNN1 | HCRTR2 4121/4885HCRTR1 3473/4885CYP11B1 2069/4885 |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | HCRTR2 3524/4885HCRTR1 3439/4885CYP11B1 69/4885 |
| US-20240076269-A1 | KCNQ POTENTIATORS | KCNN3, KCNQ1, KCNN1 | HCRTR2 4121/4885HCRTR1 3473/4885CYP11B1 2069/4885 |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | HCRTR2 3000/4885HCRTR1 2746/4885CYP11B1 61/4885 |
| US-20230271950-A1 | ANTIBACTERIAL PICOLINAMIDE COMPOUNDS | RPL35, RPL5, RPL23 | HCRTR2 2966/4885HCRTR1 2237/4885CYP11B1 4615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.